Literature DB >> 11208621

Propofol versus midazolam regarding their antioxidant activities.

M Tsuchiya1, A Asada, K Maeda, Y Ueda, E F Sato, M Shindo, M Inoue.   

Abstract

Propofol and midazolam are commonly used as sedatives for critically ill patients. These patients usually suffer from the pathologic effects of oxidative stress, predominantly caused by an imbalance between the generation of reactive oxygen species and the antioxidant defense system. Therefore, the antioxidant activities of propofol and midazolam may be of clinical importance. We investigated the activities of these two sedatives against hydrophilic or lipophilic peroxyl radicals in a homogeneous solution and in the presence of erythrocyte membranes. A chemical analysis of the homogeneous solution revealed that propofol efficiently scavenged hydrophilic peroxyl radicals (50% inhibitory concentration [IC50] = 1.3 x 10(-4) M), whereas midazolam efficiently scavenged lipophilic radicals (IC50 = 1.5 x 10(-5) M). Further, in membrane systems, propofol inhibited the oxidative damage induced by either hydrophilic or lipophilic radicals (IC50 = 1.5 x 10(-5) M for hydrophilic radicals and IC50 = 3.0 x 10(-4) M for lipophilic radicals), whereas midazolam did very little. In previous studies, we demonstrated that antioxidant activity is highly affected by the location and properties of the reaction site. The discrepancy in antioxidant activity between a homogeneous condition and in the presence of membranes can be well explained by this concept, and again emphasizes the importance of membranes in determining antioxidant activity. To further understand the biologic significance of these antioxidant properties, the effect of the two agents on endothelium-dependent relaxation was studied. Application of oxidative stress to aortic rings by treating them with peroxyl radicals led to a significant blockade of acetylcholine-induced relaxation after submaximal contraction with phenylephrine. Propofol pretreatment greatly attenuated the impairment in comparison with midazolam, which agrees with the concept of antioxidant activity in the presence of membranes. The results of the present study suggest that propofol has a greater potential to reduce oxidative stress than midazolam.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208621     DOI: 10.1164/ajrccm.163.1.9911120

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

1.  The use of propofol for medium and long-term sedation in critically ill adult patients: a meta-analysis.

Authors:  Kwok M Ho; Joseph Y Ng
Journal:  Intensive Care Med       Date:  2008-06-25       Impact factor: 17.440

2.  Effects of propofol on P2X7 receptors and the secretion of tumor necrosis factor-α in cultured astrocytes.

Authors:  Jia Liu; Xiao-Fei Gao; Wen Ni; Jin-Bao Li
Journal:  Clin Exp Med       Date:  2011-05-24       Impact factor: 3.984

3.  Comparison of the effects of propofol and midazolam on inflammation and oxidase stress in children with congenital heart disease undergoing cardiac surgery.

Authors:  Wen-fang Xia; Yu Liu; Qing-shan Zhou; Qi-zhu Tang; Han-dong Zou
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

4.  Propofol prevents endothelial dysfunction induced by glucose overload.

Authors:  Yuji Karashima; Masahiro Oike; Shosuke Takahashi; Yushi Ito
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Direct assessment of the antioxidant properties of midazolam by electron spin resonance spectroscopy.

Authors:  Mitsuuru Hata; Kyo Kobayashi; Fumihiko Yoshino; Ayaka Yoshida; Shuta Sugiyama; Chihiro Miyamoto; Fumiaki Tokutomi; Yojiro Maehata; Satoko Wada-Takahashi; Shun-Suke Takahashi; Tomoko Komatsu; Kazu-Ichi Yoshida; Masaichi-Chang-Il Lee
Journal:  J Anesth       Date:  2011-06-18       Impact factor: 2.078

6.  Evaluation of the ROS Inhibiting Activity and Mitochondrial Targeting of Phenolic Compounds in Fibroblast Cells Model System and Enhancement of Efficiency by Natural Deep Eutectic Solvent (NADES) Formulation.

Authors:  Erwann Durand; Jérôme Lecomte; Rashmi Upasani; Béatrice Chabi; Christelle Bayrasy; Bruno Baréa; Elodie Jublanc; Martyn J Clarke; David J Moore; Jonathan Crowther; Chantal Wrutniak-Cabello; Pierre Villeneuve
Journal:  Pharm Res       Date:  2017-02-21       Impact factor: 4.200

7.  Role of MnSOD in propofol protection of human umbilical vein endothelial cells injured by heat stress.

Authors:  F Wu; X J Dong; H Q Zhang; L Li; Q L Xu; Z F Liu; Z T Gu; L Su
Journal:  J Anesth       Date:  2016-01-13       Impact factor: 2.078

8.  Propofol prevents autophagic cell death following oxygen and glucose deprivation in PC12 cells and cerebral ischemia-reperfusion injury in rats.

Authors:  Derong Cui; Li Wang; Aihua Qi; Quanhong Zhou; Xiaoli Zhang; Wei Jiang
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.752

9.  Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells.

Authors:  Rafat A Siddiqui; Mustapha Zerouga; Min Wu; Alicia Castillo; Kevin Harvey; Gary P Zaloga; William Stillwell
Journal:  Breast Cancer Res       Date:  2005-06-07       Impact factor: 6.466

10.  Expression of CCL2 and CCR2 in the hippocampus and the interventional roles of propofol in rat cerebral ischemia/reperfusion.

Authors:  Yong-Qing Guo; Li-Na Zheng; Jian-Feng Wei; Xiao-Lai Hou; Shu-Zhen Yu; Wei-Wei Zhang; Jian-Min Jing
Journal:  Exp Ther Med       Date:  2014-06-04       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.